Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking greatly increase one’s odds of living a long and healthy life. With these trends gaining ever more traction, they…
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.
Spectrum Pharma shares were halved on Thursday after the firm provided an update on its midstage cancer study some updates on its late-stage programs with the FDA.
A new analysis of data collected from more than 300,000 adolescents worldwide show that more than a third engage in risky behaviors that could lead to premature death.
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Microbot Medical shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular…
NewLink Genetics shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with Ellipses Pharma.
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for…
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Intra-Cellular Therapy shares practically doubled on Monday after the firm announced that the FDA has approved Caplyta for the treatment of schizophrenia in adults
NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy (PMM). Specifically, the top-line results are coming from the Phase 3…